Losing weight is such a slog. Will Wegovy be a silver bullet for China?
Print Edition
Danish pharmaceutical company Novo Nordisk announced earlier this month that Wegovy, the weight-loss version of the company’s high-profile, diabetes-control drug Ozempic, will soon officially hit the Chinese market.
It’s good news for a country where the 2023 China Obesity Conference estimated that half of the adults in the country are overweight or obese. It’s also good news for people seeking a silver bullet for weight control.
Ozempic injections of the “semaglutide” drug, available by prescription in China since 2021, have provoked much discussion over its potential abuse by people looking for a “quick fix” to eliminate unwanted blubber.
China approved use of Ozempic as a prescription drug only for treatment of type 2 diabetes, but that didn’t stop people from seeking to access the drug outside official channels for weight loss.
That zeal was fanned by a post from Tesla tycoon Elon Musk on his X (Twitter) account. One of Musk’s followers praised his new “awesome, fit, ripped and healthy” look, and he replied that his secret was Wegovy. The post soon became viral around the world, and China was no exception.
The most effective component in the drug is semaglutide, a glucagon-like peptide-1, or GLP-1, that regulates blood sugar, appetite and digestion. Normally it is produced by the small intestine, and its secretion increases after eating.
Wegovy has demonstrated an average weight loss of roughly 17 percent. The drug remains in the system for five to seven weeks after the last dose. Ozempic is believed to have a similar effect on obesity.
Gloria Zhang, a white-collar worker in Shanghai, said that after she learned about the effect of the injections, she wanted to try the drug immediately. Yet she found that Wegovy was too expensive to buy from overseas, so she turned to Ozempic as a second choice.
“Many people online said they were using it and seemed fine,” she said.
Zhang said she bought Ozempic online without any difficulty.
After one injection, Zhang said she didn’t suffer any apparent side effects, so she continued the injections.
The result? She lost about 1.5 kilos a month, but that wasn’t good enough for her.
“I did feel that my appetite was less than before, and the constant cravings for late night snacks were gone,” she said. “But I didn’t lose weight as fast as I expected, given the price.”
Indeed, Ozempic doesn’t come cheap. A box of three injections on Alibaba’s Ali Health Pharmacy online site costs 880 yuan (US$121). Buyers need only to tick a box saying they have been diagnosed with type 2 diabetes. No prescription from a doctor is required.
The box comes with instructions to administer one injection a week.
However, the comments section of the online product indicates that most buyers don’t have diabetes and are buying the drug to lose weight.
“This is the third time I have bought it,” commented one purchaser. “I was recently eating a bit too much, and my weight was rising again. I am hoping it will help me control my appetite.”
Some netizens mentioned side effects.
“I used two injections and lost about 4 kilos in two months, yet I felt tired and sleepy almost every day,” said one buyer.
Ozempic has at least 20 known side effects, including fatigue, headache, digestive system problems, kidney disease and even thyroid cancer.
Two domestic pharmaceutical companies in China — Hangzhou Jiuyuan Gene Engineering and Livzon Pharmaceutical Group — are poised to introduce Ozempic generic drugs, and almost 10 others are in the final stages of clinical trials.
However, the Fujian Province Consumers’ Counsil issued a warning earlier this month that it’s dangerous to use Ozempic to control weight and said even Wegovy is not a drug for everyone.
“First, it requires use under a doctor’s guidance and is suitable only for patients with a body mass index greater than 27, with at least one obesity-related complication, or for patients with simple obesity with an index greater than 30,” said Sui Jian, director of the weight loss center at Fujian Provincial People’s Hospital. “Otherwise, it may not be effective.”
Wegovy received a green light from China’s National Medical Products Administration in June, and Novo Nordisk China initiated the application process for provincial tendering and online listing for injection of the drug.
Meanwhile, e-commerce websites have started taking reservations for Wegovy, charging about 1,600 yuan. The reservations page of Ali Health Pharmacy shows that more than 100 people have booked for the drug.
Anyone who has perused self-help bookshelves or “health” advertisements in the past decade has seen the increase of easy, quick solutions to slimming down. But, actually, there is no cure-all medicine when it comes to keeping fit.
Last month, the National Health Commission of China released new guidelines for the diagnosis and treatment of obesity, highlighting the relapse incidence among people using medication containing GLP-1. The guidelines, which quoted data from the United States, claimed that nearly all patients show varying degrees of a rebound in weight when the drug is discontinued.
“Additionally, patients with obesity exhibit different responses to pharmacological treatment, and some individuals may not achieve significant weight loss — defined as a minimum of 5 percent weight reduction — through medication,” the guidelines said. “In such cases, it is recommended that the patient discontinue pharmacological treatment.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
